Jason Greenwood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason Greenwood has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Shauna M. Overgaard
Center for Digital Health, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications - Chung-Il Wi
Mayo Clinic, Rochester, MN, USA
2 shared publications - Derek W. Ebner
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications Hongfang Liu
McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX, USA
2 shared publications- John B. Kisiel
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications - Kevin Jerrold Peterson
Department of Health Sciences Research Mayo Clinic 200 First Street SW 55905 Rochester MN
2 shared publications
Latest Publications
- 3 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Longitudinal Data From a Large, Multitarget Stool DNA Colorectal Cancer Screening Program
INTRODUCTION: Multitarget stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. METHODS: We assembled a retrospective cohort of mt-sDNA tests (September 2014–July 2025) within a multisite health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality end points from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma [AA], sessile serrated lesion, and negative examinations) were calculated among high-quality examinations; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate used all screening examinations. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. RESULTS: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: AA diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had AA and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher AA (trend P = 0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. DISCUSSION: Over a decade, mt-sDNA screening achieved high colonoscopy quality but revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
- 3 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Longitudinal Data From a Large, Multitarget Stool DNA Colorectal Cancer Screening Program
INTRODUCTION: Multitarget stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. METHODS: We assembled a retrospective cohort of mt-sDNA tests (September 2014–July 2025) within a multisite health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality end points from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma [AA], sessile serrated lesion, and negative examinations) were calculated among high-quality examinations; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate used all screening examinations. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. RESULTS: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: AA diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had AA and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher AA (trend P = 0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. DISCUSSION: Over a decade, mt-sDNA screening achieved high colonoscopy quality but revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
- Open Access
- 14 May 2026
- Published by Elsevier in Journal of the National Medical Association
- Vol. 118 (4) , 789-816
A lifecycle governance and learning health system framework for trustworthy, generalizable, and sustainable human-ai partnership in clinical practice: Lessons from the asthma-guidance and prediction system (A-GPS)
- 14 May 2026
- Published by Elsevier in Journal of the National Medical Association
- Vol. 118 (4) , 789-816
Open AccessA lifecycle governance and learning health system framework for trustworthy, generalizable, and sustainable human-ai partnership in clinical practice: Lessons from the asthma-guidance and prediction system (A-GPS)
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 69-100
Clinical Informatics and Artificial Intelligence in Healthcare
This chapter provides a high-level overview of clinical informatics (CI) and artificial intelligence (AI) in healthcare. It covers foundational concepts such as electronic health records (EHRs) and data standards, current applications including Clinical Decision Support Systems (CDSS) and ambient scribing/documentation, and near-term directions for both clinicians and patients. The chapter also introduces how foundational CI systems and healthcare data are leveraged to develop AI solutions, ranging from traditional machine learning to large language models, while addressing key issues such as bias, generalizability, and regulatory considerations. Finally, the chapter examines a potential future in which decentralized AI models augment clinicians in their daily work, generate deeper clinical insights, and transform patient care through advanced predictive models and digital twins.
- 2 May 2026
- Published by IGI Global Scientific Publishing
- p. 69-100
Clinical Informatics and Artificial Intelligence in Healthcare
This chapter provides a high-level overview of clinical informatics (CI) and artificial intelligence (AI) in healthcare. It covers foundational concepts such as electronic health records (EHRs) and data standards, current applications including Clinical Decision Support Systems (CDSS) and ambient scribing/documentation, and near-term directions for both clinicians and patients. The chapter also introduces how foundational CI systems and healthcare data are leveraged to develop AI solutions, ranging from traditional machine learning to large language models, while addressing key issues such as bias, generalizability, and regulatory considerations. Finally, the chapter examines a potential future in which decentralized AI models augment clinicians in their daily work, generate deeper clinical insights, and transform patient care through advanced predictive models and digital twins.
- Open Access
- 23 January 2026
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 4 (1) , 100339
Maximizing Efficiency of Artificial Intelligence-Enabled Ambient Scribes in Outpatient Settings: A Pragmatic Approach to Structuring the Patient Appointment
- 23 January 2026
- Published by Elsevier in Mayo Clinic Proceedings: Digital Health
- Vol. 4 (1) , 100339
Open AccessMaximizing Efficiency of Artificial Intelligence-Enabled Ambient Scribes in Outpatient Settings: A Pragmatic Approach to Structuring the Patient Appointment
- Open Access
- 11 April 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e70752
Implementation of an Integrated, Clinical Decision Support Tool at the Point of Antihypertensive Medication Refill Request to Improve Hypertension Management: Controlled Pre-Post Study
Background: Improving processes regarding the management of electronic health record (EHR) requests for chronic antihypertensive medication renewals may represent an opportunity to enhance blood pressure (BP) management at the individual and population level. Objective: This study aimed to evaluate the effectiveness of the eRx HTN Chart Check, an integrated clinical decision support tool available at the point of antihypertensive medication refill request, in facilitating enhanced provider management of chronic hypertension. Methods: The study was conducted at two Mayo Clinic sites—Northwest Wisconsin Family Medicine and Rochester Community Internal Medicine practices—with control groups in comparable Mayo Clinic practices. The intervention integrated structured clinical data, including recent BP readings, laboratory results, and visit dates, into the electronic prescription renewal interface to facilitate prescriber decision-making regarding hypertension management. A difference-in-differences (DID) design compared pre- and postintervention hypertension control rates between the intervention and control groups. Data were collected from the Epic EHR system and analyzed using linear regression models. Results: The baseline BP control rates were slightly higher in intervention clinics. Postimplementation, no significant improvement in population-level hypertension control was observed (DID estimate: 0.07%, 95% CI −4.0% to 4.1%; P=.97). Of the 19,968 refill requests processed, 46% met all monitoring criteria. However, clinician approval rates remained high (90%), indicating minimal impact on prescribing behavior. Conclusions: Despite successful implementation, the tool did not significantly improve hypertension control, possibly due to competing quality initiatives and high in-basket volumes. Future iterations should focus on enhanced integration with other decision support tools and strategies to improve clinician engagement and patient outcomes. Further research is needed to optimize chronic disease management through EHR-integrated decision support systems.
- 11 April 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e70752
Open AccessImplementation of an Integrated, Clinical Decision Support Tool at the Point of Antihypertensive Medication Refill Request to Improve Hypertension Management: Controlled Pre-Post Study
Background: Improving processes regarding the management of electronic health record (EHR) requests for chronic antihypertensive medication renewals may represent an opportunity to enhance blood pressure (BP) management at the individual and population level. Objective: This study aimed to evaluate the effectiveness of the eRx HTN Chart Check, an integrated clinical decision support tool available at the point of antihypertensive medication refill request, in facilitating enhanced provider management of chronic hypertension. Methods: The study was conducted at two Mayo Clinic sites—Northwest Wisconsin Family Medicine and Rochester Community Internal Medicine practices—with control groups in comparable Mayo Clinic practices. The intervention integrated structured clinical data, including recent BP readings, laboratory results, and visit dates, into the electronic prescription renewal interface to facilitate prescriber decision-making regarding hypertension management. A difference-in-differences (DID) design compared pre- and postintervention hypertension control rates between the intervention and control groups. Data were collected from the Epic EHR system and analyzed using linear regression models. Results: The baseline BP control rates were slightly higher in intervention clinics. Postimplementation, no significant improvement in population-level hypertension control was observed (DID estimate: 0.07%, 95% CI −4.0% to 4.1%; P=.97). Of the 19,968 refill requests processed, 46% met all monitoring criteria. However, clinician approval rates remained high (90%), indicating minimal impact on prescribing behavior. Conclusions: Despite successful implementation, the tool did not significantly improve hypertension control, possibly due to competing quality initiatives and high in-basket volumes. Future iterations should focus on enhanced integration with other decision support tools and strategies to improve clinician engagement and patient outcomes. Further research is needed to optimize chronic disease management through EHR-integrated decision support systems.
- Open Access
- 17 December 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00959
Accurate and Scalable Classification of Colonoscopy Neoplasia Using Machine Learning and Natural Language Processing
INTRODUCTION: Colorectal cancer remains a leading cause of cancer associated death in the United States and colonoscopy the primary screening strategy for prevention. Rates of adenomatous and serrated neoplasia detection are inversely associated with postcolonoscopy colorectal cancer. This crucial quality metric depends on accurate ascertainment of colorectal neoplasia findings from both endoscopy and histopathology records. We aimed to assess the feasibility of a random forest machine learning model to rapidly and accurately categorize colorectal neoplasia from electronic health record data. METHODS: A retrospective cohort study compared neoplasia detection rates among individuals undergoing colonoscopy at a large academic institution to develop a rule-based algorithm to categorize colorectal neoplasia from endoscopy reports and pathology systematized nomenclature of medicine – clinical terms. This cohort provided a large training set to develop a natural language processing system using a random forest approach to automatically classify unstructured pathology findings into adenoma, serrated, or advanced neoplasms. This system was manually validated through an independent holdout set. RESULTS: The training set comprised 35,953 unstructured pathology reports with matched systematized nomenclature of medicine – clinical terms from 95,188 unstructured colonoscopy reports. The final model was assessed on an independent holdout set of 337 manually annotated procedures obtaining an area under the receiver operating characteristic curve of 0.997 (confidence interval [CI] 0.994–1), 0.99 (CI 0.98–1), and 0.99 (CI 0.98–0.99) for prediction of adenoma, serrated, and advanced lesions, respectively. DISCUSSION: The random forest-based hybrid natural language processing system for classification of colonoscopy results was both accurate and explainable. NLP combined with effective machine learning algorithms can provide a scalable strategy for colonoscopy quality monitoring.
- 17 December 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00959
Open AccessAccurate and Scalable Classification of Colonoscopy Neoplasia Using Machine Learning and Natural Language Processing
INTRODUCTION: Colorectal cancer remains a leading cause of cancer associated death in the United States and colonoscopy the primary screening strategy for prevention. Rates of adenomatous and serrated neoplasia detection are inversely associated with postcolonoscopy colorectal cancer. This crucial quality metric depends on accurate ascertainment of colorectal neoplasia findings from both endoscopy and histopathology records. We aimed to assess the feasibility of a random forest machine learning model to rapidly and accurately categorize colorectal neoplasia from electronic health record data. METHODS: A retrospective cohort study compared neoplasia detection rates among individuals undergoing colonoscopy at a large academic institution to develop a rule-based algorithm to categorize colorectal neoplasia from endoscopy reports and pathology systematized nomenclature of medicine – clinical terms. This cohort provided a large training set to develop a natural language processing system using a random forest approach to automatically classify unstructured pathology findings into adenoma, serrated, or advanced neoplasms. This system was manually validated through an independent holdout set. RESULTS: The training set comprised 35,953 unstructured pathology reports with matched systematized nomenclature of medicine – clinical terms from 95,188 unstructured colonoscopy reports. The final model was assessed on an independent holdout set of 337 manually annotated procedures obtaining an area under the receiver operating characteristic curve of 0.997 (confidence interval [CI] 0.994–1), 0.99 (CI 0.98–1), and 0.99 (CI 0.98–0.99) for prediction of adenoma, serrated, and advanced lesions, respectively. DISCUSSION: The random forest-based hybrid natural language processing system for classification of colonoscopy results was both accurate and explainable. NLP combined with effective machine learning algorithms can provide a scalable strategy for colonoscopy quality monitoring.
- 26 March 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (4) , 572-578
Identification of pancreatic cancer risk factors from clinical notes using natural language processing
- 26 March 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (4) , 572-578
Identification of pancreatic cancer risk factors from clinical notes using natural language processing
- Open Access
- 14 July 2023
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 12 (1) , e45903
The Role of Artificial Intelligence Model Documentation in Translational Science: Scoping Review
Background: Despite the touted potential of artificial intelligence (AI) and machine learning (ML) to revolutionize health care, clinical decision support tools, herein referred to as medical modeling software (MMS), have yet to realize the anticipated benefits. One proposed obstacle is the acknowledged gaps in AI translation. These gaps stem partly from the fragmentation of processes and resources to support MMS transparent documentation. Consequently, the absence of transparent reporting hinders the provision of evidence to support the implementation of MMS in clinical practice, thereby serving as a substantial barrier to the successful translation of software from research settings to clinical practice. Objective: This study aimed to scope the current landscape of AI- and ML-based MMS documentation practices and elucidate the function of documentation in facilitating the translation of ethical and explainable MMS into clinical workflows. Methods: A scoping review was conducted in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. PubMed was searched using Medical Subject Headings key concepts of AI, ML, ethical considerations, and explainability to identify publications detailing AI- and ML-based MMS documentation, in addition to snowball sampling of selected reference lists. To include the possibility of implicit documentation practices not explicitly labeled as such, we did not use documentation as a key concept but as an inclusion criterion. A 2-stage screening process (title and abstract screening and full-text review) was conducted by 1 author. A data extraction template was used to record publication-related information; barriers to developing ethical and explainable MMS; available standards, regulations, frameworks, or governance strategies related to documentation; and recommendations for documentation for papers that met the inclusion criteria. Results: Of the 115 papers retrieved, 21 (18.3%) papers met the requirements for inclusion. Ethics and explainability were investigated in the context of AI- and ML-based MMS documentation and translation. Data detailing the current state and challenges and recommendations for future studies were synthesized. Notable themes defining the current state and challenges that required thorough review included bias, accountability, governance, and explainability. Recommendations identified in the literature to address present barriers call for a proactive evaluation of MMS, multidisciplinary collaboration, adherence to investigation and validation protocols, transparency and traceability requirements, and guiding standards and frameworks that enhance documentation efforts and support the translation of AI- and ML-based MMS. Conclusions: Resolving barriers to translation is critical for MMS to deliver on expectations, including those barriers identified in this scoping review related to bias, accountability, governance, and explainability. Our findings suggest that transparent strategic documentation, aligning translational science and regulatory science, will support the translation of MMS by coordinating communication and reporting and reducing translational barriers, thereby furthering the adoption of MMS.
- 14 July 2023
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 12 (1) , e45903
Open AccessThe Role of Artificial Intelligence Model Documentation in Translational Science: Scoping Review
Background: Despite the touted potential of artificial intelligence (AI) and machine learning (ML) to revolutionize health care, clinical decision support tools, herein referred to as medical modeling software (MMS), have yet to realize the anticipated benefits. One proposed obstacle is the acknowledged gaps in AI translation. These gaps stem partly from the fragmentation of processes and resources to support MMS transparent documentation. Consequently, the absence of transparent reporting hinders the provision of evidence to support the implementation of MMS in clinical practice, thereby serving as a substantial barrier to the successful translation of software from research settings to clinical practice. Objective: This study aimed to scope the current landscape of AI- and ML-based MMS documentation practices and elucidate the function of documentation in facilitating the translation of ethical and explainable MMS into clinical workflows. Methods: A scoping review was conducted in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. PubMed was searched using Medical Subject Headings key concepts of AI, ML, ethical considerations, and explainability to identify publications detailing AI- and ML-based MMS documentation, in addition to snowball sampling of selected reference lists. To include the possibility of implicit documentation practices not explicitly labeled as such, we did not use documentation as a key concept but as an inclusion criterion. A 2-stage screening process (title and abstract screening and full-text review) was conducted by 1 author. A data extraction template was used to record publication-related information; barriers to developing ethical and explainable MMS; available standards, regulations, frameworks, or governance strategies related to documentation; and recommendations for documentation for papers that met the inclusion criteria. Results: Of the 115 papers retrieved, 21 (18.3%) papers met the requirements for inclusion. Ethics and explainability were investigated in the context of AI- and ML-based MMS documentation and translation. Data detailing the current state and challenges and recommendations for future studies were synthesized. Notable themes defining the current state and challenges that required thorough review included bias, accountability, governance, and explainability. Recommendations identified in the literature to address present barriers call for a proactive evaluation of MMS, multidisciplinary collaboration, adherence to investigation and validation protocols, transparency and traceability requirements, and guiding standards and frameworks that enhance documentation efforts and support the translation of AI- and ML-based MMS. Conclusions: Resolving barriers to translation is critical for MMS to deliver on expectations, including those barriers identified in this scoping review related to bias, accountability, governance, and explainability. Our findings suggest that transparent strategic documentation, aligning translational science and regulatory science, will support the translation of MMS by coordinating communication and reporting and reducing translational barriers, thereby furthering the adoption of MMS.
- Open Access
- 25 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The Role of Artificial Intelligence Model Documentation in Translational Science: Scoping Review (Preprint)
BACKGROUND Despite the touted potential of artificial intelligence (AI) and machine learning (ML) to revolutionize health care, clinical decision support tools, herein referred to as medical modeling software (MMS), have yet to realize the anticipated benefits. One proposed obstacle is the acknowledged gaps in AI translation. These gaps stem partly from the fragmentation of processes and resources to support MMS transparent documentation. Consequently, the absence of transparent reporting hinders the provision of evidence to support the implementation of MMS in clinical practice, thereby serving as a substantial barrier to the successful translation of software from research settings to clinical practice. OBJECTIVE This study aimed to scope the current landscape of AI- and ML-based MMS documentation practices and elucidate the function of documentation in facilitating the translation of ethical and explainable MMS into clinical workflows. METHODS A scoping review was conducted in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. PubMed was searched using Medical Subject Headings key concepts of AI, ML, ethical considerations, and explainability to identify publications detailing AI- and ML-based MMS documentation, in addition to snowball sampling of selected reference lists. To include the possibility of implicit documentation practices not explicitly labeled as such, we did not use documentation as a key concept but as an inclusion criterion. A 2-stage screening process (title and abstract screening and full-text review) was conducted by 1 author. A data extraction template was used to record publication-related information; barriers to developing ethical and explainable MMS; available standards, regulations, frameworks, or governance strategies related to documentation; and recommendations for documentation for papers that met the inclusion criteria. RESULTS Of the 115 papers retrieved, 21 (18.3%) papers met the requirements for inclusion. Ethics and explainability were investigated in the context of AI- and ML-based MMS documentation and translation. Data detailing the current state and challenges and recommendations for future studies were synthesized. Notable themes defining the current state and challenges that required thorough review included bias, accountability, governance, and explainability. Recommendations identified in the literature to address present barriers call for a proactive evaluation of MMS, multidisciplinary collaboration, adherence to investigation and validation protocols, transparency and traceability requirements, and guiding standards and frameworks that enhance documentation efforts and support the translation of AI- and ML-based MMS. CONCLUSIONS Resolving barriers to translation is critical for MMS to deliver on expectations, including those barriers identified in this scoping review related to bias, accountability, governance, and explainability. Our findings suggest that transparent strategic documentation, aligning translational science and regulatory science, will support the translation of MMS by coordinating communication and reporting and reducing translational barriers, thereby furthering the adoption of MMS.
- 25 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Role of Artificial Intelligence Model Documentation in Translational Science: Scoping Review (Preprint)
BACKGROUND Despite the touted potential of artificial intelligence (AI) and machine learning (ML) to revolutionize health care, clinical decision support tools, herein referred to as medical modeling software (MMS), have yet to realize the anticipated benefits. One proposed obstacle is the acknowledged gaps in AI translation. These gaps stem partly from the fragmentation of processes and resources to support MMS transparent documentation. Consequently, the absence of transparent reporting hinders the provision of evidence to support the implementation of MMS in clinical practice, thereby serving as a substantial barrier to the successful translation of software from research settings to clinical practice. OBJECTIVE This study aimed to scope the current landscape of AI- and ML-based MMS documentation practices and elucidate the function of documentation in facilitating the translation of ethical and explainable MMS into clinical workflows. METHODS A scoping review was conducted in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. PubMed was searched using Medical Subject Headings key concepts of AI, ML, ethical considerations, and explainability to identify publications detailing AI- and ML-based MMS documentation, in addition to snowball sampling of selected reference lists. To include the possibility of implicit documentation practices not explicitly labeled as such, we did not use documentation as a key concept but as an inclusion criterion. A 2-stage screening process (title and abstract screening and full-text review) was conducted by 1 author. A data extraction template was used to record publication-related information; barriers to developing ethical and explainable MMS; available standards, regulations, frameworks, or governance strategies related to documentation; and recommendations for documentation for papers that met the inclusion criteria. RESULTS Of the 115 papers retrieved, 21 (18.3%) papers met the requirements for inclusion. Ethics and explainability were investigated in the context of AI- and ML-based MMS documentation and translation. Data detailing the current state and challenges and recommendations for future studies were synthesized. Notable themes defining the current state and challenges that required thorough review included bias, accountability, governance, and explainability. Recommendations identified in the literature to address present barriers call for a proactive evaluation of MMS, multidisciplinary collaboration, adherence to investigation and validation protocols, transparency and traceability requirements, and guiding standards and frameworks that enhance documentation efforts and support the translation of AI- and ML-based MMS. CONCLUSIONS Resolving barriers to translation is critical for MMS to deliver on expectations, including those barriers identified in this scoping review related to bias, accountability, governance, and explainability. Our findings suggest that transparent strategic documentation, aligning translational science and regulatory science, will support the translation of MMS by coordinating communication and reporting and reducing translational barriers, thereby furthering the adoption of MMS.
- 1 February 2022
- Published by Elsevier in Primary Care Diabetes
- Vol. 16 (1) , 78-83
Association of a housing based individual socioeconomic status measure with diabetic control in primary care practices
- 1 February 2022
- Published by Elsevier in Primary Care Diabetes
- Vol. 16 (1) , 78-83
Association of a housing based individual socioeconomic status measure with diabetic control in primary care practices